Indian firm secures drug patents in five countries

The granted patents are exclusive intellectual property of Suven Life Sciences Ltd. and are achieved through the internal discovery research efforts

The Dollar Business Bureau

Hyderabad-based biopharmaceutical manufacturer Suven Life Sciences Ltd. on Thursday announced that it has secured five product patents in China, Israel, Mexico, Singapore and Sri Lanka. The patents will be used to treat disorders associated with Neurodegenerative diseases. “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven Life Sciences Ltd. Among the granted patents is the class of selective 5-HT compounds, which was discovered by Suven earlier this year. The patents are being developed as therapeutic agents and will be used to treat neurodegenerative disorders, including attention deficient hyperactivity disorder (ADHD), Alzheimer’s, Schizophrenia, and Huntington’s disease. With the latest announcement, Suven has 17 granted patents from China, 7 from Israel, 20 from Mexico, 21 from Singapore and 11 from Sri Lanka. “These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,” said the company in a statement. Suven has three clinical stage compounds, a Phase 1 completed candidate SUVN-G3031, Phase 2 initiated candidate SUVN-502, and Phase 1 initiated candidate SUVN-D4010 for Schizophrenia and Alzheimer’s. The company also has ten discovered therapeutic drug candidates at its pre-clinical stage of development. These drugs will be used to treat attention deficit hyperactivity disorder (ADHD), depression, dementia, Parkinson’s disease, Huntington’s disease and pain.  In 2014, Suven had developed intermediates for three new chemical entities (NCEs) to address depression, diabetes and rheumatoid arthritis.  

September 10, 2015 | 1:15pm IST.


The Dollar Business Bureau - Sep 10, 2015 12:00 IST